Let’s start up with the current stock price of Avalo Therapeutics Inc. (AVTX), which is $2.40 to be very precise. The Stock rose vividly during the last session to $2.70 after opening rate of $2.67 while the lowest price it went was recorded $2.525 before closing at $2.56.Recently in News on September 14, 2021, Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock. Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases, announced today that it has entered into an underwriting agreement with Jefferies LLC and RBC Capital Markets, LLC under which the underwriters agreed to purchase, on a firm commitment basis, 12,500,000 shares of common stock of the Company, at a public offering price of $2.20 per share (the “Public Offering Price”). The offering is expected to close on or about September 17, 2021, subject to customary closing conditions. You can read further details here
Avalo Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.50 on 02/22/21, with the lowest value was $2.06 for the same time period, recorded on 05/13/21.
Avalo Therapeutics Inc. (AVTX) full year performance was -7.58%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Avalo Therapeutics Inc. shares are logging -46.67% during the 52-week period from high price, and 21.21% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.98 and $4.50.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1771721 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Avalo Therapeutics Inc. (AVTX) recorded performance in the market was -3.03%, having the revenues showcasing -28.09% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 249.45M, as it employees total of 32 workers.
Market experts do have their say about Avalo Therapeutics Inc. (AVTX)
During the last month, 0 analysts gave the Avalo Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.94, with a change in the price was noted -0.17. In a similar fashion, Avalo Therapeutics Inc. posted a movement of -6.67% for the period of last 100 days, recording 1,414,847 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AVTX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.79.
Technical breakdown of Avalo Therapeutics Inc. (AVTX)
Raw Stochastic average of Avalo Therapeutics Inc. in the period of last 50 days is set at 17.86%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 18.87%. In the last 20 days, the company’s Stochastic %K was 11.33% and its Stochastic %D was recorded 12.06%.
Bearing in mind the latest performance of Avalo Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -3.03%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -22.19%, alongside a downfall of -7.58% for the period of the last 12 months. The shares increased approximately by -11.42% in the 7-day charts and went down by -10.80% in the period of the last 30 days. Common stock shares were lifted by -28.09% during last recorded quarter.